Weight-loss drug developers line up to tap lucrative market as competition heats up

Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows

This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica

Interview with Sandoz CEO Richard Saynor on Generic Pharmaceuticals Industry

This article discusses an interview with Richard Saynor, head of Sandoz, focusing on the generic pharmaceuticals industry and its difference

Inside the Gold Rush: Black-Market Peptide Testing and the Race to Cash In on Legalization

The article covers the booming black-market peptide and anabolic steroid industry, focusing on Janoshik Analytical, a purity testing company

Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation